Enveric Biosciences Inc., a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, announced positive results from a preclinical study of its lead drug candidate, EB-003. The study demonstrated that EB-003 significantly decreased context-induced freezing behavior in a well-established rodent model for post-traumatic stress disorder (PTSD) when measured one hour after administration. These results suggest a positive therapeutic effect and rapid fear extinction. EB-003, a neuroplastogen, may enhance hippocampal neuroplasticity without causing hallucinations, potentially improving treatment outcomes for PTSD. Current FDA-approved treatments, such as SSRIs, only result in full remission for 20% to 30% of patients and require several weeks before benefits are observed. The study compared EB-003's effects to those of MDMA, a controlled substance that has shown clinical benefits in PTSD treatment but is not FDA-approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.